Modeling the lifecycle of ebola virus under biosafety level 2 conditions with virus-like particles containing tetracistronic minigenomes

Journal of Visualized Experiments

Volumn , Issue 91, 2014, Pages

  Hoenen, Thomas ^a   Watt, Ari ^a   Mora, Anita ^a   Feldmann, Heinz ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Budding; Ebola virus; Entry; Filovirus; Hemorrhagic Fevers; Infectious Diseases; Issue 91; Lifecycle modeling system; Minigenome; Mononegavirales Infections; Morphogenesis; Replication; Reverse genetics; Transcription; Viral; Virus like particles

Indexed keywords

EBOLAVIRUS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEK293 CELL LINE; HUMAN; LIFE CYCLE STAGE; PROCEDURES; SAFETY; STANDARDS; VIRION; VIROLOGY; VIRUS GENOME;

EBOLAVIRUS; GENOME, VIRAL; HEK293 CELLS; HUMANS; LIFE CYCLE STAGES; SAFETY; VIRION; VIROLOGY;

EID: 84908283335     PISSN: 1940087X     EISSN: None     Source Type: Journal    
DOI: 10.3791/52381     Document Type: Article

References (18)

1. Kuhn, J. H, et al. Evaluation of perceived threat differences posed by filovirus variants. Biosecurity and bioterrorism: Biodefense strategy, practice, and science. 9, 361-371, doi:10.1089/bsp.2011.0051 (2011).
2. Falzarano, D., & Feldmann, H. Possible leap ahead in filovirus therapeutics. Cell research. 26, doi:10.1038/cr.2014.49 (2014).
3. Hoenen, T., Groseth, A., & Feldmann, H. Current ebola vaccines. Expert opinion on biological therapy. 12, 859-872, doi:10.1517/14712598.2012.685152 (2012).
4. Beniac, D. R, et al. The organisation of ebola virus reveals a capacity for extensive, modular polyploidy. PloS one. 7, 29608, doi:10.1371/journal.pone.0029608 (2012).
5. Basu, A., Mills, D. M., & Bowlin, T. L. High-throughput screening of viral entry inhibitors using pseudotyped virus. Current protocols in pharmacology/editorial board, S.J. Enna. Chapter 13, Unit 13B 13, doi:10.1002/0471141755.ph13b03s51 (2010).
6. Wong, A. C., Sandesara, R. G., Mulherkar, N., Whelan, S. P., & Chandran, K. A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry. J Virol. 84, 163-175, doi:10.1128/JVI.01832-09 (2010).
7. Muhlberger, E., Weik, M., Volchkov, V. E., Klenk, H. D., & Becker, S. Comparison of the transcription and replication strategies of marburg virus and Ebola virus by using artificial replication systems. J Virol. 73, 2333-2342 (1999).
8. Hoenen, T., Groseth, A., de Kok-Mercado, F., Kuhn, J. H., & Wahl-Jensen, V. Minigenomes, transcription and replication competent virus-like particles and beyond: reverse genetics systems for filoviruses and other negative stranded hemorrhagic fever viruses. Antiviral Res. 91, 195-208, doi:10.1016/j.antiviral.2011.06.003 (2011).
9. Hoenen, T., & Feldmann, H. Reverse genetics systems as tools for the development of novel therapies against filoviruses. Expert Rev Anti Inf Ther. 24, 1253-1263, doi: 10.1586/14787210.2014.948848 (2014).
10. Hoenen, T, et al. Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol. 80, 7260-7264, doi:10.1128/JVI.00051-06 (2006).
11. Watanabe, S. et al. Production of novel ebola virus-like particles from cDNAs: an alternative to ebola virus generation by reverse genetics. J Virol. 78, 999-1005 (2004).
12. Hoenen, T., Jung, S., Herwig, A., Groseth, A., & Becker, S. Both matrix proteins of Ebola virus contribute to the regulation of viral genome replication and transcription. Virology. 403, 56-66, doi:10.1016/j.virol.2010.04.002 (2010).
13. Watanabe, S., Noda, T., Halfmann, P., Jasenosky, L., & Kawaoka, Y. Ebola virus (EBOV) VP24 inhibits transcription and replication of the EBOV genome. J Infect Dis. 196 Suppl 2, 284-290 doi:10.1086/520582 (2007).
14. Spiegelberg, L, et al. Genus-specific recruitment of filovirus ribonucleoprotein complexes into budding particles. J Gen Virol. 92, 2900-2905, doi:10.1099/vir.0.036863-0 (2011).
15. Watt, A, et al. A novel lifecycle modeling system for Ebola virus shows a genome length-dependent role of VP24 on virus infectivity. J Virol. 88, doi:10.1128/JVI.01272-14 (2014).
16. Kondratowicz, A. S, et al. T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A. 108, 8426-8431, doi:10.1073/pnas.1019030108 (2011).
17. Hoenen, T., Groseth, A., Callison, J., Takada, A., & Feldmann, H. A novel Ebola virus expressing luciferase allows for rapid and quantitative testing of antivirals. Antiviral Res. 99, 207-213, doi:10.1016/j.antiviral.2013.05.017 (2013).
18. Hoenen, T, et al. Inclusion bodies are a site of ebolavirus replication. J Virol 86, 11779-11788, doi:10.1128/JVI.01525-12 (2012).